Newsroom

latest news from ose
and across our portfolio

Featured News

Portfolio news – Oxford Ionics reaches agreement to be acquired by IonQ for $1.075 Billion
Portfolio news – Oxford Ionics reaches agreement to be acquired by IonQ for $1.075 Billion
Oxford Spinout Oxford Semantic Technologies acquired by Samsung Electronics
Oxford Spinout Oxford Semantic Technologies acquired by Samsung ElectronicsArticle links to www.oxionics.com
Oxford Ionics breaks global quantum performance records
Oxford Ionics breaks global quantum performance records
Times Commentary: Science innovation must be at the heart of government action
Times Commentary: Science innovation must be at the heart of government actionArticle links to www.beacontx.com
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies
Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesArticle links to www.prnewswire.com
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptography
PQShield raises $37m in Series B funding to deliver the widespread commercial adoption of quantum resistant cryptographyArticle links to www.globenewswire.com
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
Amber Therapeutics Closes $100 Million Series A - one of the largest European MedTech raises
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group
OSE announces groundbreaking new partnership with The Crown Estate and Pioneer Group

All News

Portfolio NewsBeacon TherapeuticsBeacon Therapeutics completes enrolment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRPPortfolio NewsBeacon TherapeuticsBeacon Therapeutics appoints Dr. Daniel Chung as Chief Medical OfficerPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive Phase 2 Interim 6-Month Data from DAWN Trial of Laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP) at ARVO 2025Portfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive 3-Month Data from Phase 2 DAWN Trial of laru-zova (AGTC-501) in Patients with X-Linked Retinitis Pigmentosa (XLRP)Portfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis PigmentosaPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial OfficerPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene TherapiesPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Treats First Patient in VISTA Registrational Trial for AGTC-501Portfolio NewsBeacon TherapeuticsAscend acquires GMP manufacturing capacity in Alachua, Florida; Enters long-term partnership with Beacon Therapeutics for clinical and commercial AAV productionPortfolio NewsBeacon TherapeuticsBeacon Therapeutics Announces Positive 12-Month Data from Trial of Patients with X-Linked Retinitis PigmentosaPortfolio NewsBeacon TherapeuticsBeacon Therapeutics launches with £96 million to develop a new generation of gene therapies for retinal diseases